Fundamental and clinical studies on the efficacy of bifonazole in patients with tinea pedis at 10 years after approval part 2. Clinical evaluation

Japanese Journal of Antibiotics

Volumn 49, Issue 12, 1996, Pages 58-60

  Watanabe, Shin Ichi ^a   Takahashi, Hisashi ^a   Nakamura, Yuka ^b   Nakamura, Emi ^c   Nishiyama, Yuichi ^d   Teduka, Mayuri ^e   Yamaguchi, Hideyo ^f   Uchida, Katsuhisa ^g   Tomizawa, Takanori ^h   Shimozuma, Michiro ⁱ   Osada, Atsushi ^j   Kawano, Shihomi ^a   Nakauchi, Youichi ^a   Wakukawa, Motoshi ^b   Goto, Atsuko ^c   Ueda, Yoshitsugu ^d   Matsukawa, Ataru ^e   Minami, Haruo ^f   Arikawa, Junko ^g   Soma, Yoshinao ^h   Chi, Hymg In ⁱ   Tamaki, Kunihiko ^j   more..

^a TEIKYO UNIVERSITY   (Japan)

^b KANTO ROSAI HOSPITAL   (Japan)

^c Kosei General Hospital   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e University of Tokyo   (Japan)

^f Social Health Insurance Medical Center   (Japan)

^g JR Tokyo General Hospital   (Japan)

^h TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

ⁱ Odaira Memorial Tokyo Hitachi Hospital   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIFONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; DERMATOMYCOSIS; DRUG EFFICACY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; TINEA PEDIS; TOPICAL DRUG ADMINISTRATION;

ADULT; AGED; ANTIFUNGAL AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; TINEA PEDIS; TRICHOPHYTON;

EID: 33749312464     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Mycological activity Mycological examination results became negative in 63.2% (36/57) of the patients with plantar tinea pedis, in 94.1% (32/34) of those with interdigital tinea pedis, and in 74.7% (68/91) of all tinea pedis patients.
2. Mycological activity and MIC No correlation was found between the MICs of bifonazole against the pathogenic fungi and the rate of eradication on mycological examination.
3. Improvement of symptoms The improvement rates for local symptoms were 82.5% for plantar tinea pedis, 85.7% for interdigital tinea pedis, and 83.7% for all tinea pedis.
4. Clinical efficacy Good clinical efficacies were found in 61.4% of the patients with plantar tinea pedis, in 88.6% of those with interdigital tinea pedis, and in 71.7% of all patients.
5. Safety Regarding adverse reactions, what seemed to be contact dermatitis was reported in 5 out of 127 cases (3.9%). The reaction decreased or disappeared in all cases.
6. Usefulness Mycospor® was found to be useful in 64.9% of patients with plantar tinea pedis, in 88.6% of those with interdigital tinea pedis, and in 73.9% of all tinea pedis patients.
7. Comparison with former results The results obtained in the present clinical study were comparable to those obtained in patients with tinea pedis treated in a double-blind comparative study conducted during the development of as a new topical antifungal agent. From the above results, Mycospor® cream was confirmed to be still useful, although it has been used widely for the topical treatment of cutaneous mycoses in the past 10 years since its approval.
8. Bifonazoleo Bifonazole Jap. J. Antibiotics 49: 1085-1094, 1996
9. KP-363 Butenafine Hydrochloride (KP-363) Well-Controlled Comparative Study 52: 1012-1024, 1990
10. 4) Well-Controlled Comparative Study ICJ;5 Bifonazole 25: 4609-4625, 1991
11. Terbinafine Terbinafine Well-Controlled Comparative Study Bifonazole 4 53: 1268-1287, 1991
12. MT-861 Bifonazole Well-Controlled Comparative Study 4 54: 101-113, 1992